Inventor · disambiguated record
Peter Lamb
Also filed as: LAMB PETER · LAMB PETER I
14 granted patents·13 pending applications·298 citations·filing 1999–2025
94Inventor score
Top patents by PatentIndex Score
27 records- 0197US11098015B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 24, 2021·9 cites·3 claims
- 0297US11091440B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Granted Aug 17, 2021·8 cites·3 claims
- 0397US11091439B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2020·Granted Aug 17, 2021·8 cites·5 claims
- 0495US9809549B2Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2014·Granted Nov 7, 2017·30 cites·5 claims
- 0595US7999006B2Methods of using MEK inhibitorsEXELIXIS INC·Filed 2007·Granted Aug 16, 2011·51 cites·27 claims
- 0694US8877776B2(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideBROWN ADRIAN ST CLAIR·Filed 2010·Granted Nov 4, 2014·61 cites·5 claims
- 0794US7704995B2Protein kinase modulators and methods of useEXELIXIS INC·Filed 2003·Granted Apr 27, 2010·64 cites·35 claims
- 0892US12275706B2Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2024·Granted Apr 15, 2025·0 cites·6 claims
- 0991US11065240B2Drug combinations to treat multiple myelomaEXELIXIS INC·Filed 2015·Granted Jul 20, 2021·6 cites·4 claims
- 1089US2024279181A1Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2024·Application pending·0 cites
- 1188US8642584B2Method of using PI3K and MEK modulatorsAFTAB DANA T·Filed 2012·Granted Feb 4, 2014·22 cites·2 claims
- 1285US2023167063A1Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2023·Application pending·0 cites
- 1381US2025243165A1Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2025·Application pending·0 cites
- 1480US8513266B2Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alphaLAMB PETER·Filed 2008·Granted Aug 20, 2013·5 cites·9 claims
- 1580US8481001B2Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancerLAMB PETER·Filed 2008·Granted Jul 9, 2013·5 cites·13 claims
- 1679US2022033357A1Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1778US2022259151A9Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1873US2020190032A1Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancerEXELIXIS INC·Filed 2020·Application pending·0 cites
- 1967US6498155B1Methods of treating thrombocytopeniaSMITHKLINE BEECHAM CORP·Filed 1999·Granted Dec 24, 2002·29 cites·12 claims
- 2067US2018002289A1Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2017·Application pending·0 cites
- 2167US2018037552A1Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2017·Application pending·0 cites
- 2267US2017275251A1Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerEXELIXIS INC·Filed 2017·Application pending·0 cites
- 2355US2010075947A1Methods of Using PI3K and MEK ModulatorsEXELIXIS INC·Filed 2007·Application pending·0 cites
- 2453US2023301979A1Combinations for the treatment of cancerEXELIXIS INC·Filed 2021·Application pending·0 cites
- 2552US2014100215A1Methods of Using PI3K and MEK ModulatorsEXELIXIS INC·Filed 2013·Application pending·0 cites
- 2641US8802692B2Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agentsSHANKAR GEETHA·Filed 2009·Granted Aug 12, 2014·0 cites·51 claims
- 2737US2004053299A1Regulated activation of cell-membrane receptors by metal-chelating agonistsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Lamb files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →